Collaborations & Alliances

Kite Pharma Expands Partnership with NCI

Will collaborate with the experimental transplantation and immunology branch

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Kite Pharma has entered into a research and development agreement with The National Cancer Insitute (NCI) for the research and clinical development of a fully human anti-CD19 chimeric antigen receptor (CAR) product candidate for the treatment of B-cell lymphomas and leukemias. Kite will collaborate with Jim Kochenderfer, an investigator in the experimental transplantation and immunology branch of the NCI, to evaluate this product candidate in a Phase 1 clinical study this year. In addition, t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters